INTRODUCTION:Niemann-Pick disease type C (NPC) is a lysosomal storage disorder that leads to progressive neurodegeneration. The glucosylceramide synthase blocker miglustat is being used to treat NPC, but monitoring of disease progression and treatment response is difficult. NPC patients have elevated cerebrospinal fluid (CSF) levels of total-tau (T-tau) indicating axonal degeneration, and increased CSF amyloid β (Aβ) indicating abnormal brain amyloid metabolism, but it is unknown if start of miglustat treatment affects these biomarker levels. METHODS: Biomarkers were measured in serial CSF samples from NPC patients who started miglustat between samplings (N=5), were untreated at both samplings (N=5) or received treatment during the whole study (N=6) (median time between samplings 309 days [range 175-644]). CSF was analyzed for Aβ(38), Aβ(40), Aβ(42), α-cleaved soluble APP, β-cleaved soluble APP, T-tau and phospho-tau. RESULTS:T-tau levels decreased in patients who started miglustat treatment (median 955 [range 338-1,271]ng/L at baseline vs. 382 [187-736]ng/L at follow-up, p=0.043). Untreated patients and continuously treated patients had stable levels (p>0.05). No changes were seen in the other biomarkers. CONCLUSION: Reduced CSF T-tau suggests that miglustat treatment might affect axonal degeneration in NPC. However, the results must be interpreted with caution and verified in future studies, since this pilot study was small, treatment was not randomized, and patients starting treatment had higher baseline CSF T-tau than untreated patients.
RCT Entities:
INTRODUCTION:Niemann-Pick disease type C (NPC) is a lysosomal storage disorder that leads to progressive neurodegeneration. The glucosylceramide synthase blocker miglustat is being used to treat NPC, but monitoring of disease progression and treatment response is difficult. NPCpatients have elevated cerebrospinal fluid (CSF) levels of total-tau (T-tau) indicating axonal degeneration, and increased CSF amyloid β (Aβ) indicating abnormal brain amyloid metabolism, but it is unknown if start of miglustat treatment affects these biomarker levels. METHODS: Biomarkers were measured in serial CSF samples from NPCpatients who started miglustat between samplings (N=5), were untreated at both samplings (N=5) or received treatment during the whole study (N=6) (median time between samplings 309 days [range 175-644]). CSF was analyzed for Aβ(38), Aβ(40), Aβ(42), α-cleaved soluble APP, β-cleaved soluble APP, T-tau and phospho-tau. RESULTS: T-tau levels decreased in patients who started miglustat treatment (median 955 [range 338-1,271]ng/L at baseline vs. 382 [187-736]ng/L at follow-up, p=0.043). Untreated patients and continuously treated patients had stable levels (p>0.05). No changes were seen in the other biomarkers. CONCLUSION: Reduced CSF T-tau suggests that miglustat treatment might affect axonal degeneration in NPC. However, the results must be interpreted with caution and verified in future studies, since this pilot study was small, treatment was not randomized, and patients starting treatment had higher baseline CSF T-tau than untreated patients.
Authors: N Mattsson; H Zetterberg; S Bianconi; N M Yanjanin; R Fu; J-E Månsson; F D Porter; K Blennow Journal: Neurology Date: 2010-12-29 Impact factor: 9.910
Authors: Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Lars Lannfelt; Stig Strid; Peter Annas; Hans Basun; Niels Andreasen Journal: Neurosci Lett Date: 2007-04-06 Impact factor: 3.046
Authors: Henrik Zetterberg; Mona Pedersen; Karin Lind; Maria Svensson; Sindre Rolstad; Carl Eckerström; Steinar Syversen; Ulla-Britt Mattsson; Christina Ysander; Niklas Mattsson; Arto Nordlund; Hugo Vanderstichele; Eugeen Vanmechelen; Michael Jonsson; Ake Edman; Kaj Blennow; Anders Wallin Journal: J Alzheimers Dis Date: 2007-11 Impact factor: 4.472
Authors: Victor L Villemagne; D Velakoulis; V Doré; S Bozinoski; C L Masters; C C Rowe; Mark Walterfang Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-28 Impact factor: 9.236
Authors: Niklas Mattsson; Maria Olsson; Mikael K Gustavsson; Marko Kosicek; Martina Malnar; Jan-Eric Månsson; Maria Blomqvist; Johan Gobom; Ulf Andreasson; Gunnar Brinkmalm; Charles Vite; Silva Hecimovic; Caroline Hastings; Kaj Blennow; Henrik Zetterberg; Erik Portelius Journal: Metab Brain Dis Date: 2012-09-01 Impact factor: 3.584
Authors: Brett Tortelli; Hideji Fujiwara; Jessica H Bagel; Jessie Zhang; Rohini Sidhu; Xuntian Jiang; Nicole M Yanjanin; Roopa Kanakatti Shankar; Nuria Carillo-Carasco; John Heiss; Elizabeth Ottinger; Forbes D Porter; Jean E Schaffer; Charles H Vite; Daniel S Ory Journal: Hum Mol Genet Date: 2014-06-25 Impact factor: 6.150
Authors: Marcello Esposito; Raffaele Dubbioso; Stefano Tozza; Rosa Iodice; Marco Aiello; Emanuele Nicolai; Carlo Cavaliere; Marco Salvatore; Lucio Santoro; Fiore Manganelli Journal: Heliyon Date: 2019-11-14
Authors: Steven U Walkley; Cristin D Davidson; Jonathan Jacoby; Philip D Marella; Elizabeth A Ottinger; Christopher P Austin; Forbes D Porter; Charles H Vite; Daniel S Ory Journal: Orphanet J Rare Dis Date: 2016-12-01 Impact factor: 4.303
Authors: Antony Cougnoux; Julia C Yerger; Mason Fellmeth; Jenny Serra-Vinardell; Kyle Martin; Fatemeh Navid; James Iben; Christopher A Wassif; Niamh X Cawley; Forbes D Porter Journal: Int J Mol Sci Date: 2020-07-28 Impact factor: 5.923